FAQs

PET Theranostics is Australia’s first dedicated PET-CT and CT diagnostic imaging centre for pets, bringing world-class technology used in human cancer care into veterinary medicine. The service combines advanced imaging, research, and innovation to give veterinarians and pet owners the most precise diagnostic insights. Every scan helps improve cancer detection, treatment planning, and outcomes for companion animals.

PET Theranostics partners with veterinarians, offering advanced imaging and clinically actionable reports that enhance diagnosis, treatment planning, and ongoing management. For pet owners, this means faster answers, clearer information, and confidence in making informed care decisions. The team ensures every patient remains under the care of their primary vet while benefiting from specialist diagnostic expertise.

A PET-CT scan combines two powerful technologies — Positron Emission Tomography (PET) and Computed Tomography (CT) — to show the structure and function of tissues. It uses molecular tracers to detect disease activity at a cellular level, revealing information invisible to standard imaging. PET-CT is especially valuable in cancer diagnosis, staging, treatment planning, and monitoring, helping vets understand how the disease behaves inside the body.

A CT scan focuses on structure, showing what tissues and organs look like in detail. It uses X-rays and computer processing to produce 3D images of bones, soft tissue, and internal organs. CT is commonly used in veterinary medicine to detect tumours, diagnose nasal or chest conditions, assess joints and bones, plan surgeries, and monitor treatment outcomes. It’s a safe, fast, and non-invasive procedure that provides the clarity needed for accurate diagnosis.

Theranostics is an advanced approach that combines diagnosis and treatment into one integrated pathway. Using molecular imaging like PET-CT, disease can be identified and mapped precisely. The same tracer can be paired with a therapeutic isotope to deliver targeted treatment directly to diseased cells, minimising harm to healthy tissue. Already established in human oncology, theranostics is being developed for veterinary use, offering personalised treatment with fewer side effects.

PET Theranostics was founded with a commitment to combine clinical excellence with research. Every scan contributes to a growing body of knowledge that helps refine imaging protocols, validate new tracers, and explore the potential of theranostic therapies in veterinary medicine. This research is shared across the veterinary community, lifting standards and advancing cancer care for companion animals.

Pets benefit from early and accurate diagnosis, personalised treatment options, and world-class imaging technology. This translates into greater peace of mind for families, as care decisions are informed by the most precise information available. Every scan helps the individual pet and contributes to a broader understanding of cancer in animals, shaping the future of veterinary oncology.

PET Theranostics’ theranostic treatment service is currently under development and will be launched soon. The team is actively engaged in research and clinical validation to ensure the highest standards of safety and effectiveness. Once available, this breakthrough technology will enable Australian vets and pet owners to access targeted cancer treatments that are already transforming human medicine.